AVJ16 – has blocked the cancer-driving RNA-binding protein IGF2BP1 in preclinical lung cancer models, curbing tumour growth while sparing healthy tissue, in ...
The health impacts of men losing their Y chromosome from their cells are increasingly coming to light, with the loss playing ...
The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...
Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now ...
Approximately 20% of new lung cancer diagnoses occur in nonsmokers in the U.S., according to The Ohio State University ...
If everyone eligible had a lung cancer screening, 62,000 lives would be saved over five years, a new study shows.
A year after she quit smoking, Kim Swart thought the half-million cigarettes she smoked between high school and retirement ...
Summit Therapeutics' Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism.
Cellular therapies, including TIL, TCR, and CAR-T, are transforming lung cancer care by utilizing personalized immune cells ...
When Sydney Barned was first diagnosed with stage 4 lung cancer, she was just 33 years old — a young medical intern focused ...
DPI-4452 targets CAIX in tumors, offering noninvasive diagnostic potential for ccRCC with favorable tolerability. The agent is part of a theranostic pair wi ...
ChristianaCare’s Gene Editing Institute says it has found a way to reverse chemotherapy resistance in one of the most common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback